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Iranian populationAbstract Background: Polymorphisms of different gene have been reported to be associated with
cancer including breast cancer. Hospitalization rate for breast cancer has increased over the years in
Iran.
Aim: The aim of this study was to examine whether polymorphisms in the CYP3A4 and
CYP3A5 genes affect the risk of developing breast cancer.
Subjects and methods: The genotype distribution and allele frequencies of four CYP3A4*1A,
CYP3A4*1B, CYP3A5*1 and CYP3A5*3 single-nucleotide polymorphisms were determined in
250 subjects from the general population in Ahvaz city (southwest of Iran) including 200 healthy
subjects and 50 individuals affected with breast cancer.
Results and conclusion: The genotype frequency of CYP3A4*1A/*1A (A/A) in both case and
control groups was 100%; however, there was no subject with either CYP3A4 * 1A/ * 1B (A/G)
or CYP3A4*1B/*1B (G/G) genotype. For CYP3A5 gene, CYP3A5*3/*3mutant homozygote
genotype frequency was found to be 99% (n= 198) and 98% (n= 49) in control and patient
groups respectively. CYP3A5*1/*1 wild-type genotype was calculated to be 1% (n = 2) in the
control group and 2% (n = 1) in the case group. No. CYP3A5*1/*3 heterozygote genotype was
detected in the both groups. The results showed that there was no association between breast
cancer, CYP3A5 (P-value = 0.561) and CYP3A4 allele distribution.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The numerous endogenous compounds such as estrogen and
testosterone are metabolized by a heme-containing enzyme
named cytochrome P450 (CYP) [1,18]. CYP3A subfamily
220 E. Badavi et al.isoforms activate plenty of procarcinogenic polycyclic
aromatic hydrocarbon dihydrodiols and metabolize N0-
nitrosonornicotine [2]. Polymorphisms of CYP3A gene
involved in carcinogen metabolism may affect individual varia-
tion in cancer susceptibility [3,4] and the response to anticancer
therapy [5,6]. Moreover, the CYP3A gene participates in meta-
bolism of many pharmaceutical and recreational drugs; there-
fore, it has been widely studied in industrialized populations.
CYP3A subfamily has two predominant isoforms including
CYP3A4 and CYP3A5 enzymes which are expressed in human
liver, small intestine jejunum, colon, breast, prostate and
pancreas [7–12]. Both genes have variant alleles all occurring
at low frequencies in various ethnic populations [13]. Several
SNPs affecting enzyme function have been reported for
CYP3A5 gene [14].
It has been shown that a frequent single nucleotide poly-
morphism (SNP) of CYP3A5gene, 6896A>G, is associated
with CYP3A5 enzyme production and activity [14]. The
G>A mutation in intron 3 of the gene leading to a splice
defect of the mRNA produces an unstable and nonfunctional
protein. The mutated allele and the wild type were named
CYP3A5*3(rs776746) and CYP3A5*1, respectively. Only
individuals carrying at least one CYP3A5*1 allele can express
high levels of CYP3A5 enzyme [15]. CYP3A5*3 allele on the
other hand, causes alternative splicing and blocks protein pro-
duction resulting in either reduced or lost CYP3A5 enzyme
activity [8,16]. CYP3A4 is the major CYP in human hepatic
tissue and also expressed in the breast which has an important
role in the oxidation of both testosterone (2b-, 6b-, or 15b-
hydroxytestosterone) and estrogen (4- and 16a-hydroxylation)
[17,18]. CYP3A4 exhibits a common variant in the 50-ﬂanking
region (290) designated CYP3A4*1B(rs2740574) [19]. In
comparison with the wild-type CYP3A4*1A, CYP3A4*1B
shows about a 2-fold increase in enzyme activity [18].
CYP3A4*1B leads to an amino acid change resulting in altered
protein function and is associated with a variety of cancers
including prostate cancer and leukemia in individuals treated
with epipodophyllotoxin [20–22]. Although CYP3A4*1B
causes an amino acid change, there is no signiﬁcant difference
between the CYP3A4*1B variant and the wild-type enzymes in
the metabolism of testosterone, progesterone, or 7-benzyloxy-
4 (triﬂuoromethyl) coumarin [23]. Not only inter-individual dif-
ferences in the expression level resulting in tumor development
have been connected with CYP3A5 and CYP3A4 polymor-
phisms, but polymorphism frequencies also differ remarkably
among different human populations [24,25]. Even though these
polymorphisms are well characterized in different populations,Figure 1 Chromatogram of CYP3A4*1A sequence result by Chroma
one peak.there is not enough data about the Iranian ethnic group.
Furthermore, the association study of these polymorphisms
with breast cancer is the ﬁrst cross-sectional investigation in
the world. The aim of the present study is addition valuable data
to association studies ofCYP3A5 andCYP3A4with cancer sus-
ceptibility. We were going to study the possible association of
CYP3A5*3 and CYP3A4*1B SNPs with breast cancer.
2. Subjects and methods
2.1. Subjects
A total of 250 subjects were included in the study consisting of
200 female healthy individuals aged 24–70 years (mean age
44.89 ± 14.30) and 50 unrelated patients suffering from breast
cancer aged 20–65 years (mean 41.98 ± 13.91) collected at the
Hospitals of Jundishapur University (Ahvaz-southwest of
Iran). Ethical approval for this study was obtained from the
Ethics Committee of Jundishapur University of Medical
Sciences, Ahvaz, Iran.
2.2. Genotype analysis
Whole-blood genomic DNA was extracted using the diatom
DNA kit (IsoGene, Russia), according to the manufacturer’s
recommendations. The DNA quantity and quality were deter-
mined by Nano-Drop (ND1000; NanoDrop Technologies,
Wilmington, DE) and proved to be implemented efﬁciently
as template for PCR. Then, they were stored at 20 C until
genotyping. To genotype the A6986G polymorphism in the
CYP3A5 gene, polymerase chain reaction (PCR) (Bio-Rad
Company – T100 Thermal Cycler Model) based on the
restriction fragment length polymorphism (RFLP) was used
as described by Tsuchiya et al. method [26]. The designed
primers for CYP3A5 were F: 50-ATGGAGAGTGGCATA
GGAGATA-30 and R: 50-TGTGGTCCAAACAGGGAAGA
AATA-30. Reaction mixtures consisted of 40–50 ng DNA,
1.5 mM master mix, 10 pmol each primer and 1 U Taq poly-
merase (Qiagen Company), and deionized water to a volume
of 25 ll. The PCR for amplifying CYP3A5 was carried out
by the following: initial heating at 94 C for 10 min, 40 cycles
of 94 C for 30 s, 56 C for 45 s, and 72 C for 30 s and a ﬁnal
extension at 72 C for 5 min. Afterward, the PCR products
(130 bp) were digested with restriction enzyme SspI
(Fermentas, USA, Catalogue number: ER0771). When the A
allele of CYP3A5 was present, it was divided into 107 ands program. Homozygote individuals for A/A genotype present only
Figure 2 Chromatogram of CYP3A5*3 sequence result by Chromas program. Homozygote individuals for G/G genotype present only
one peak.
Figure 3 Chromatogram of CYP3A5*1 sequence result by Chromas program. Homozygote individuals for A/A genotype present only
one peak.
Table 1 Allele and genotype frequencies of CYP3A4 and
CYP3A5 genes in breast cancer patients and healthy subjects in
Iranian population.
SNP Patient
group
(n= 50)
Control
group
(n= 200)
**p-value for
Hardy–Weinberg
equilibrium
*N % N %
CYP3A5
*3/*3(G/G) 49 98 198 99 0.561
*1/*3(A/G) 0 0 0 0
*1/*1(A/A) 1 2 2 1
CYP3A5*3(G)
allele
49 98 198 99
CYP3A5*1(A)
allele
1 2 2 1
CYP3A4
*1A/*1A(A/A) 50 100 200 100
*1A/*1B(A/G) 0 0 0 0
*1B/*1B(G/G) 0 0 0 0
CYP3A4*1A(A)
allele
50 100 200 100
CYP3A4*1B(G)
allele
0 0 0 0
* N = population size.
** P-values express whether Iranian population is similar to
respective populations.
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ose gel. Unlikely, two-step PCR-RFLP assay was carried out
for genotyping of a CYP3A4*1A/B SNP at the promoter
region. First, 319-bp PCR product was produced, then
secondary PCR using nested primers ampliﬁed 168-bp PCR
product. As mentioned earlier, PCR reaction mixtures were
prepared. The designed primers used for the ﬁrst PCR reaction
were FI: 50-CTGGAGCTGTGGCTTGTTGG-30 and RI:
50-CGAAGCAGGGCTGGAGCTGC-30. For amplifying, the
PCR conditions were: 95 C for 1 min for an initial denat-
uration, 40 cycles of 95 C for 45 s, 63 C for 30 s, and 72 C
for 30 s and a ﬁnal extension at 72 C for 5:30 min. Nested
primers used for the secondary PCR reaction were FII: 50-
GGACAGCCATAGAGACAAGGCCA-30 and RII: 50-CAC
TCACTGACCTCCTTTGAGTTCA-30. Ampliﬁcation condi-
tions of the ﬁrst and second PCR reactions were alike. ScrFI
restriction enzyme (Fermentas; USA) digestion of the sec-
ondary PCR product results in CYP3A4*1A homozygote’s
(168-bp fragment) and CYP3A4*1B homozygote’s (146-bp
and 22-bp fragments) which were shown by 2.5% agarose
gel. Several samples were randomly selected and directly
sequenced to validate the results of the study (Figs. 1–3).
2.3. Statistical analysis
The v2-test was used to determine if the allele and genotype fre-
quencies of polymorphisms ﬁt the Hardy–Weinberg equilib-
rium and to compare the obtained results between healthy
and affected subjects. Analysis was performed with SPSS soft-
ware (Statistical Package for the Social Sciences, version 18,
SSPS Inc., Chicago, IL, USA), with P-values < 0.05 as the
statistical signiﬁcance. The obtained results were compared
between different populations.3. Results
In the present study, the allele and genotype frequencies of
CYP3A4*1B/*1A and CYP3A5*3/*1 SNPs were determined
in 250 subjects from the general population in Ahvaz city
222 E. Badavi et al.(southwest of Iran) including 200 healthy subjects and 50
individuals affected with breast cancer. The genotype fre-
quency of CYP3A4*1A/*1A (A/A) in the both case and con-
trol groups was 100%; however, there was no subject with
either CYP3A4 * 1A/ * 1B (A/G) orCYP3A4*1B/*1B (G/G)
genotype. Since all subjects had the same genotype (A/A),
v2-test was not performed in order to statistically analyze the
genotype frequencies of CYP3A4 gene in the studied pop-
ulation. For CYP3A5 gene, CYP3A5*3/*3mutant homozygote
genotype frequency was found to be 99% (n= 198) and 98%
(n= 49) in control and patient groups respectively.
CYP3A5*1/*1 wild-type genotype, on the other hand, was cal-
culated to be 1% (n= 2) in the control group and 2% (n= 1)
in the case group. No CYP3A5*1/*3 heterozygote genotype
was detected in both groups.
CYP3A5*3 (G) allele frequencies were 99% in healthy
individuals and 98% in patients. Moreover, allele frequency
of CYP3A5*1 (A) was 1% and 2% in the control group and
patient group respectively. The results showed that there was
no statistical difference between cases and control and that
the CYP3A5 (P-value = 0.561) and CYP3A4 genotypes were
not detected among certain groups (Table 1).
4. Discussion
Breast cancer is the most prevalent malignancy among Iranian
women [27]. Many genetic-conditions such as sickle cell disease
and thalassemias are well known in Iran. Therefore it was
assumed that genetic conditions may have a signiﬁcant impact
on breast cancer. The present study was conducted to explore
the probable association between cancer-related polymor-
phisms with the risk of breast cancer among Iranian pop-
ulation. In addition, determination of CYP3A4 and CYP3A5
variant alleles and knowledge about their allelic frequency inTable 2 The comparison between CYP3A5 genotype and allele fre
Population N* CYP3A5 genotype freque
*3/*3 *3/*
(G/G) (G/A
Asian
Iranian(Ahvaz city) 200 198 0
Iranian(shiraz city) 100 98 2
Chinese(2005) 302 190 90
Chinese(2014) 240 116 103
Japanese 400 242 130
European
Poland 100 93 7
Dutch Caucasian 1000 831 167
Spanish 163 135 27
Bosnia& 139 120 19
Herzegovina
American
American Indian 94 80 13
Brazilian 799 500 263
African
Cameroon 72 0 25
South African 155 14 41
* N = population size,
** P-values express whether Iranian population is similar to respective pIranian population may lead to individualized drug dosing
and improved breast cancer therapeutics.
CYP3A5 genotype and allele frequencies were compared
between this study and other studies done on different ethnic
populations in the world. Iran is a country which has a large
population with different ethnic groups; therefore, the studied
population in Ahvaz city (southwest of Iran) can be compared
to the population investigated in Shiraz city (south of Iran)
[27]. The results of v2-test showed that there was no signiﬁcant
difference in the genotype frequencies of CYP3A5 between the
two populations (P-value = 0.082). The present study was also
compared with other Asian populations, and the comparison
showed that CYP3A5 genotype distribution differed from
Chinese (P-value < 0.0001) [28,29] and Japanese populations
(P-value < 0.0001) [30]. Genotype frequencies of CYP3A5
were also signiﬁcantly different from Europeans such
as Poland (P-value < 0.0001) [31], Dutch Caucasian
(P-value < 0.0001) [32], Spain (P-value < 0.0001) [33],
Bosnia, and Herzegovina (P-value < 0.0001) [34]. There were
signiﬁcant differences between this study and the studies on
Americans such as American Indians (P-value < 0.0001) [35]
and Brazilians (P-value < 0.0001) [36]. Genotype distribution
of CYP3A5 was also different from African countries, includ-
ing Cameroon and South Africa (P-value < 0.0001) [37]
(Table 2). So our study indicated that there were noticeable
interethnic variations in the frequencies of alleles and genotype
for the CYP3A5 polymorphisms among Iranian populations
and African, American and Asian populations.
CYP3A4 genotype distribution was also compared between
Iranian population and other Asians. The v2-test results
showed that there was considerable similarity genotype dis-
tribution of CYP3A4 gene in the population investigated in
Shiraz city. As all subjects in both groups had the (A/A) geno-
type, no statistical analysis was carried out [27]. In contrast,quencies in Iran and other countries.
ncy(%) P-value** References
1 *1/*1
) (A/A)
2 This study
0 0.082 [27]
2 <0.0001 [28]
21 <0.0001 [29]
28 <0.0001 [30]
0 <0.0001 [31]
2 <0.0001 [32]
1 <0.0001 [33]
0 <0.0001 [34]
1 <0.0001 [35]
36 <0.0001 [36]
47 <0.0001 [37]
100 <0.0001 [37]
opulations.
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Figure 4 Comparison between Incidence rates of breast cancer
in ﬁve different ethnic groups and Iranian population.
Association of CYP3A4 and CYP3A5 polymorphisms 223CYP3A4 genotype frequencies were signiﬁcantly different
from Mixed-Ancestry (P-value < 0.0001) [38] and Jordanian
populations (P-value < 0.0001) [39]. The result of Chi-square
test demonstrated that the genotype distribution of CYP3A4
remarkably differed from European countries, including
Poland (P-value = 0.001) [31] and Bosnia and Herzegovina
(P-value = 0.001) [34]. There was also a noticeable difference
between Iranian and Spanish populations (P-value < 0.0001)
[33]. In addition, the genotype frequencies of CYP3A4 were
different between this study and American Indian population
(P-value = 0.003) [35]. The comparison between CYP3A4
genotype frequencies in this study and the studies on African
countries, including Cameroon (P-value < 0.0001) [37],
South Africa (P-value < 0.0001) [37], Xhosa (P-value < 0.0001)
[38], and Khoisan (P-value < 0.0001) [38] showed there was
considerable dissimilarity (Table 3). Our study indicated that
there were noticeable interethnic variations in the frequencies
of alleles and genotype for the CYP3A4 polymorphisms
among Iranian populations and European and African
populations.
The allele and genotype frequencies in CYP3A enzymes
may contribute greatly to variation in oral bioavailability
and systemic clearance of CYP3A substrates including numer-
ous common therapy drugs and endogenous molecules such as
the oxidation of testosterone and the hydroxylation of estro-
gens [40]. There was a difference in the frequencies of breast
cancer in different ethnic groups. Epidemiological evidence
reported the relationship of breast cancer frequency (cases
per 100,000). The alleles and genotypes frequencies were found
signiﬁcantly different among African, American, Asian and
Caucasian populations [40]. The incidence of breast cancer in
Iranian women was 22 per 100,000 and the incidence rate of
breast cancer in Iran was raised to 93 cases per 100,000 in
2013 [41]. This incidence (in 2007) was less than the incidence
rate in African, American, Asian and Caucasian populationsTable 3 The comparison between CYP3A4 genotype and allele fre
Population N* CYP3A4 genotype frequency (%
*1A/*1A (A/A) *1A/*1B
Asian
Iranian(Ahvaz city) 200 200 0
Iranian(shiraz city)
Jordanian
100
173
100
161
0
12
Mixed-Ancestry 65 19 32
European
Poland 100 95 5
Spanish 163 149 14
Bosnia& 138 131 7
Herzegovina
American
American Indian 94 90 4
African
Cameroon 69 41 26
South African 153 78 47
Xhosa
Khoisan
65
29
5
2
25
10
* N = population size.
** P-values express whether Iranian population is similar to respective p(Fig. 4) [40]. Although few studies have investigated a role
for CYP3A enzymes activity in breast cancer risk, taken
together, previous studies suggest evidence that the major
polymorphic variants in CYP3A4 may be associated with ster-
oid metabolism related to breast cancer.
CYP3A4*1B in Iranian population is lower than its fre-
quencies in Hispanic population (0.000 in this study).
Frequencies of the CYP3A4*1B variant among African
Americans is 0.817, among Caucasian is 0.096, among
Hisponish is 0.107, among Asian is 0.000 and unknown in
Native Americans. The ﬁve populations frequencies of
CYP3A4*1B are poorly correlated with breast cancer inci-
dence (P-value > 0.1). The results show no association with
breast cancer and CYP3A4*1B polymorphism and compar-
ison between Incidence rates of breast cancer in ﬁve different
ethnic groups, therefore there is no association between breast
cancer and frequency of CYP3A4 enzymes activity in most
populations.quencies in Iran and other countries.
) P-value** References
(A/G) *1B/*1B (G/G)
0 This study
0
0

<0.0001
[27]
[39]
14 <0.0001 [38]
0 0.001 [31]
0 <0.0001 [33]
0 0.001 [34]
0 0.003 [35]
2 <0.0001 [37]
28 <0.0001 [37]
35
17
<0.0001 [38]
<0.0001 [38]
opulations.
224 E. Badavi et al.5. Conclusion
In conclusion, the results obtained show that 98% of our sam-
ple do not carry a mutant allele. Ethnic and geographic differ-
ences may explain discrepancies in the prevalence of CYP3A4
and CYP3A5 polymorphisms. Genotype distribution studies
could provide valuable information to help further investiga-
tions of association between polymorphisms and several types
of cancer. A large database may allow for a more precise esti-
mate of these associations.6. Conﬂict of interest
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